Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor fraction in cell-free DNA as a biomarker in prostate cancer

1 Nov 2018

Abstract excerpt

BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30385733
DOI: 10.1172/jci.insight.122109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor fraction in cell-free DNA as a biomarker in prostate cancerPMID 30385733Read ↗

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.Semantic proximity Read ↗

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.Semantic proximity Read ↗

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerSemantic proximity Read ↗

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Semantic proximity Read ↗

Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)Semantic proximity Read ↗

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemantic proximity Read ↗

Cell-free DNA concentration and fragment size as a biomarker for prostate cancerSemantic proximity Read ↗

Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.Semantic proximity Read ↗

Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancerSemantic proximity Read ↗

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.